Rosemberg E, Cortes-Prieto J
Fertil Steril. 1983 Dec;40(6):790-7. doi: 10.1016/s0015-0282(16)47481-9.
This study presents the first demonstration of the ability of a hybrid human chorionic gonadotropin (hCG) compound, AB1ER-CR-2XY, to induce ovulation in humans. Thirteen patients with primary infertility were treated for 16 cycles with varying dosages of human menopausal gonadotropin (hMG), and 10,000, 5000, and 2500 IU of the hybrid hCG. Presumptive occurrence of ovulation was recorded in 15 courses of medication. Echographic studies did not indicate overt follicular or ovarian enlargement. Two singleton pregnancies occurred, one during the first treatment course and the other following the second course of hMG/hybrid hCG therapy. Due to its specific characteristics, the hybrid hCG may provide equal or greater effectiveness and a better margin of safety than commercial hCG used for ovulation induction in patients pretreated with hMG.
本研究首次证明了一种人绒毛膜促性腺激素（hCG）复合药物AB1ER-CR-2XY诱导人类排卵的能力。13例原发性不孕症患者接受了不同剂量的人绝经期促性腺激素（hMG）以及10000、5000和2500国际单位的复合hCG治疗，共16个周期。在15个疗程的用药中记录到推测的排卵情况。超声检查未显示明显的卵泡或卵巢增大。发生了2例单胎妊娠，1例在第一个疗程期间，另1例在hMG/复合hCG治疗的第二个疗程之后。由于其特定特性，与用于接受hMG预处理患者排卵诱导的市售hCG相比，复合hCG可能具有同等或更高的有效性以及更好的安全边际。
